Abstract:Acute respiratory distress syndrome (ARDS) is an inflammatory lung disease with a high morbidity and mortality rate, for which no pharmacologic treatment is currently available. Our previous studies discovered that a pivotal step in the disease process is the activation of the nuclear factor of activated T cells (NFAT) c3 in lung macrophages, suggesting that inhibitors against the upstream protein phosphatase calcineurin should be effective for prevention/treatment of ARDS. Herein, we report the development of a highly potent, cell-permeable, and metabolically stable peptidyl inhibitor, CNI103, which selectively blocks the interaction between calcineurin and NFATc3, through computational and medicinal chemistry. CNI103 specifically inhibited calcineurin signaling in vitro and in vivo and exhibited a favorable pharmacokinetic profile, broad tissue distribution following different routes of administration, and minimal toxicity. Our data indicate that CNI103 is a promising novel treatment for ARDS and other inflammatory diseases.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01236?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01236</a>.Table of additional acyl groups subjected to in silico screening and their calculated binding energies to calcineurin; table of sequences of hit peptides from OBOC library screening; table of stability of CNI103 upon incubation with mouse hepatocytes; tables of stability of CNI103 in simulated gastric fluid, intestinal fluid, and mouse liver microsomes; table of plasma concentration of CNI103 at different time points; structure and synthesis of OBOC peptide library; representative MALDI-TOF mass spectra of peptides derived from hit beads; representative binding curves of FITC-labeled peptides 13, 14, 16, and 19; turbidity test; effect of CN inhibitors on cell viability; effect of CNI93 on recruitment of neutrophils into lungs, on pulmonary function, on mouse body weight, and on the phosphatase activity of GST-CN toward p-nitrophenyl phosphate; CNI95 lacking ex vivo efficacy in prevention of LPS-induced cytokine production; intracellular stability of CNI103 in HCT116 cells; biodistribution of CNI103 in mice; selective uptake of CNI103Cy5 into immune cell subsets in vivo; ALI parameters in mice 24 h after LPS challenge; dose response of CNI103 for prevention of LPS-induced ALI; quantitation of TNFα levels in lung and kidney tissues of mice; and analytical HPLC tracings and MS data of peptides (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01236/suppl_file/jm0c01236_si_001.pdf">PDF</a>)Molecular formula strings of peptides (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01236/suppl_file/jm0c01236_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

A Novel Peptide Exerts Potent Immunosuppression by Blocking the Two-Site Interaction of NFAT with Calcineurin

A Polypeptide Inhibitor of Calcineurin Blocks the Calcineurin-Nfat Signalling Pathway in Vivo and in Vitro

A Peptidyl Inhibitor that Blocks Calcineurin–NFAT Interaction and Prevents Acute Lung Injury

An artificial peptide inhibits autophagy through calcineurin-TFEB pathway

PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced ColitiS

A Peptide Derived from IKK-Interacting Protein Attenuates NF-κB Activation and Inflammation.

Anti-inflammatory Effects of a Novel Peptide Designed to Bind with NF-κB P50 Subunit

NLRP3 Inflammasome Inhibitor INF39 Attenuated NLRP3 Assembly in Macrophages.

Quercetin Targets the Interaction of Calcineurin with LxVP-type Motifs in Immunosuppression.

Development of a Decafluorobiphenyl Cyclized Peptide Targeting the NEMO–IKKα/β Interaction That Enhances Cell Penetration and Attenuates Lipopolysaccharide-Induced Acute Lung Injury

Peptides Derived from Transcription Factor EB Bind to Calcineurin at a Similar Region As the NFAT-type Motif

A TNF-α blocking peptide that reduces NF-κB and MAPK activity for attenuating inflammation

A Neuropeptide Y/F-like Polypeptide Derived from the Transcriptome of Turbinaria peltata Suppresses LPS-Induced Astrocytic Inflammation

Novel peptide inhibitor of human tumor necrosis factor-α has antiarthritic activity

Structure-Based Optimization of a Peptidyl Inhibitor Against Calcineurin-Nuclear Factor of Activated T Cell (NFAT) Interaction

A Novel Peptide Derived from Human Pancreatitis-Associated Protein Inhibits Inflammation in Vivo and in Vitro and Blocks NF-kappa B Signaling Pathway.

Nanoparticle-Assisted Transcutaneous Delivery of a Signal Transducer and Activator of Transcription 3-Inhibiting Peptide Ameliorates Psoriasis-like Skin Inflammation

Anti-Cytokine Active Immunotherapy Based on Supramolecular Peptides for Alleviating IL-1β-Mediated Inflammation

Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders

Quercitrin: a New Immunosuppressant Inhibits Calcineurin*

Development of a Highly Efficient Hybrid Peptide That Increases Immunomodulatory Activity Via the TLR4-Mediated Nuclear Factor-κB Signaling Pathway